drug costs Archives
Study finds Mark Cuban’s Cost Plus Drug Company could save taxpayers millions on Medicare generic oncology drugs
Jun. 8, 2023—Vanderbilt research finds that the U.S. government could save taxpayers between $228 million-$2.15 billion a year if insurers who operate its Medicare Part D plans purchased seven generic oncology drugs at the same prices obtained by the Mark Cuban Cost Plus Drug Company.
Feb. 9, 2023—Vanderbilt research found that a new drug company founded by entrepreneur Mark Cuban could save patients $1.29 billion a year based on 2020 Medicare Part D expenditures on just the nine most popular urological drugs.
Nov. 3, 2022—Vanderbilt's Stacie Dusetzina, PhD, and several colleagues were able to reflect recently on the South Lawn of the White House about how their contributions through research and data informed the provisions in the Inflation Reduction Act that will save older Americans on Medicare tens of thousands of dollars in out-of-pocket costs each year.
May. 10, 2022—A new study by Vanderbilt researchers highlights how some older Americans diagnosed with cancer can face unlimited out-of-pocket spending for prescription drugs under the current structure of the Medicare Part D benefit.
Study finds sexual minority communities disproportionately engage in behaviors to reduce medication costs
Jan. 6, 2022—Vanderbilt research finds that individuals from sexual minority populations, including members of the lesbian, gay, bisexual and queer communities, are more likely than heterosexual individuals to engage in behaviors to reduce medication costs.
Aug. 9, 2018—As both drug prices and out-of-pocket expense for prescription medications continue to climb, a team of Health Policy experts at Vanderbilt University School of Medicine (VUSM) have received a grant to determine if these factors are causing older Americans enrolled in Medicare Part D for medication coverage to delay or never fill their prescriptions.
May. 9, 2018—Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released this week.